Literature DB >> 16166593

Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia.

Wei Liu1, Meng Guo, Ya-Bei Xu, Dao Li, Zhao-Nian Zhou, Ying-Li Wu, Zhu Chen, Scott C Kogan, Guo-Qiang Chen.   

Abstract

We showed previously that mild real hypoxia and hypoxia-mimetic agents induced in vitro cell differentiation of acute myeloid leukemia (AML). We here investigate the in vivo effects of intermittent hypoxia on syngenic grafts of leukemic blasts in a PML-RARalpha transgenic mouse model of AML. For intermittent hypoxia, leukemic mice were housed in a hypoxia chamber equivalent to an altitude of 6000 m for 18 hours every consecutive day. The results show that intermittent hypoxia significantly prolongs the survival of the leukemic mice that received transplants, although it fails to cure the disease. By histologic and cytologic analyses, intermittent hypoxia is shown to inhibit the infiltration of leukemic blasts in peripheral blood, bone marrow, spleen, and liver without apoptosis induction. More intriguingly, intermittent hypoxia also induces leukemic cells to undergo differentiation with progressive increase of hypoxia-inducible factor-1alpha protein, as evidenced by morphologic criteria of maturating myeloid cells and increased expression of mouse myeloid cell differentiation-related antigens Gr-1 and Mac-1. Taken together, this study represents the first attempt to characterize the in vivo effects of hypoxia on an AML mouse model. Additional investigations may uncover ways to mimic the differentiative effects of hypoxia in a manner that will benefit human patients with AML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166593     DOI: 10.1182/blood-2005-03-1278

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Intermittent hypobaric hypoxia preconditioning induced brain ischemic tolerance by up-regulating glial glutamate transporter-1 in rats.

Authors:  Shu-Juan Gong; Ling-Yu Chen; Min Zhang; Jian-Xue Gong; Ya-Xian Ma; Jian-Mei Zhang; Yu-Jing Wang; Yu-Yan Hu; Xiao-Cai Sun; Wen-Bin Li; Yi Zhang
Journal:  Neurochem Res       Date:  2011-11-12       Impact factor: 3.996

2.  Targeted genes and interacting proteins of hypoxia inducible factor-1.

Authors:  Wei Liu; Shao-Ming Shen; Xu-Yun Zhao; Guo-Qiang Chen
Journal:  Int J Biochem Mol Biol       Date:  2012-05-31

3.  PML-RARα enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway.

Authors:  Ying Huang; Jia-Kai Hou; Ting-Ting Chen; Xu-Yun Zhao; Zhao-Wen Yan; Jing Zhang; Jie Yang; Scott C Kogan; Guo-Qiang Chen
Journal:  Autophagy       Date:  2011-10-01       Impact factor: 16.016

4.  HIF-1α downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation.

Authors:  M He; Q-Y Wang; Q-Q Yin; J Tang; Y Lu; C-X Zhou; C-W Duan; D-L Hong; T Tanaka; G-Q Chen; Q Zhao
Journal:  Cell Death Differ       Date:  2012-10-12       Impact factor: 15.828

5.  RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation.

Authors:  Sigal Gery; Dorothy J Park; Peter T Vuong; Renu K Virk; Claudia I Muller; Wolf-K Hofmann; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

6.  Commonly dysregulated genes in murine APL cells.

Authors:  Wenlin Yuan; Jacqueline E Payton; Matthew S Holt; Daniel C Link; Mark A Watson; John F DiPersio; Timothy J Ley
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

Review 7.  MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers.

Authors:  Mehdi Sajjadi-Dokht; Talar Ahmad Merza Mohamad; Heshu Sulaiman Rahman; Marwah Suliman Maashi; Svetlana Danshina; Navid Shomali; Saeed Solali; Faroogh Marofi; Elham Zeinalzadeh; Morteza Akbari; Ali Adili; Ramin Aslaminabad; Majid Farshdousti Hagh; Mostafa Jarahian
Journal:  Genes Dis       Date:  2021-12-03

Review 8.  Differentiation therapy revisited.

Authors:  Hugues de Thé
Journal:  Nat Rev Cancer       Date:  2017-12-01       Impact factor: 60.716

9.  (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.

Authors:  Julie-Aurore Losman; Ryan E Looper; Peppi Koivunen; Sungwoo Lee; Rebekka K Schneider; Christine McMahon; Glenn S Cowley; David E Root; Benjamin L Ebert; William G Kaelin
Journal:  Science       Date:  2013-02-07       Impact factor: 47.728

Review 10.  What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.

Authors:  Julie-Aurore Losman; William G Kaelin
Journal:  Genes Dev       Date:  2013-04-15       Impact factor: 12.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.